Vinylbital

Last updated
Vinylbital
Vinylbital structure.svg
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic
Excretion Renal
Identifiers
  • 5-(1-methylbutyl)-5-vinylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.017.633 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H16N2O3
Molar mass 224.260 g·mol−1
3D model (JSmol)
  • O=C1NC(=O)NC(=O)C1(\C=C)C(C)CCC
  • InChI=1S/C11H16N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h5,7H,2,4,6H2,1,3H3,(H2,12,13,14,15,16) Yes check.svgY
  • Key:KGKJZEKQJQQOTD-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Vinylbital, also known as butylvinal, is a sedative hypnotic drug which is a barbiturate derivative. [1] It was developed by Aktiebolaget Pharmacia in the 1950s. [2] [ failed verification ]

Related Research Articles

<span class="mw-page-title-main">Pharmacia</span> Pharmaceutical and biotechnological company

Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995.

<span class="mw-page-title-main">Valdecoxib</span> Nonsteroidal anti-inflammatory drug

Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. It was patented in 1995.

<span class="mw-page-title-main">Pharmacia & Upjohn</span>

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

<span class="mw-page-title-main">Amersham plc</span> Former British radiopharmaceutical manufacturer

Amersham plc was a manufacturer of radiopharmaceutical products, to be used in diagnostic and therapeutic nuclear medicine procedures. The company became GE Healthcare following a takeover in 2003, which was based at the original site in Amersham, Buckinghamshire until 2016, when the headquarters moved to Chicago.

G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company. Searle is most notable for having developed the first female birth control pill, and the artificial sweetener NutraSweet. Searle also invented the drug Lomotil that enabled space travel by humans, and was the drug taken by Neil Armstrong to stop bowel movements prior to the Apollo Program. One of the notable Alumni of Searle is Donald Rumsfeld, the Secretary of State for Bush in the 2000s and the mastermind behind preemptive war. Prior to its 1985 merger with Monsanto, Searle was a company mainly focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

<span class="mw-page-title-main">Upjohn</span> Pharmaceutical manufacturing firm

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Hastings, Michigan, by Dr. William E. Upjohn who was an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. They could be "reduced to a powder under the thumb", a strong marketing argument at the time.

Sepharose is a tradename for a crosslinked, beaded-form of agarose, a polysaccharide polymer material extracted from seaweed. Its brand name is a portmanteau derived from Separation-Pharmacia-Agarose. A common application for the material is in chromatographic separations of biomolecules.

<span class="mw-page-title-main">Semaxanib</span> Chemical compound

Semaxanib (SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.

<span class="mw-page-title-main">Benproperine</span> Chemical compound

Benproperine (INN) is a cough suppressant. It has been marketed in multiple countries in Central America and Europe, as the phosphate or pamoate salts in either tablet, dragée, or syrup form. Trade names include Blascorid in Italy and Sweden, Pectipront and Tussafug in Germany, and Pirexyl in Scandinavia. The recommended dosage for adults is 25 to 50 mg two to four times daily, and for children 25 mg once or twice daily. Adverse effects include dry mouth, dizziness, fatigue, and heartburn.

Nealbarbital (Censedal) is a barbiturate derivative developed by Aktiebolaget Pharmacia in the 1950s. It has sedative and hypnotic effects, and was used for the treatment of insomnia.

Phadia develops, manufactures and markets blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases. The company is headquartered in Uppsala, Sweden. It has been owned by Thermo Fisher Scientific since 2011.

Robert B. Shapiro is a businessman and attorney who has worked extensively with the biochemical corporations G. D. Searle & Company and Monsanto. Before working in this sector he was Vice-President and legal counsel at General Instrument from 1972 to 1979. His father, Moses, was Chairman of this company from 1969 to 1975.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

Jerker Porath, was a Swedish biochemist who invented several separation methods for biomolecules. He was born in Sala.

<span class="mw-page-title-main">Tofenacin</span> Chemical compound

Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia. It acts as a serotonin-norepinephrine reuptake inhibitor, and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.

<span class="mw-page-title-main">PNU-181731</span> Chemical compound

PNU-181731 is a drug which acts as an agonist at serotonin 5-HT2 receptors, with strongest binding affinity for the 5-HT2C subtype at 4.8nM, and weaker 5-HT2A affinity of 18nM. It has anxiolytic effects in animal studies with around one tenth the potency of alprazolam and no significant ataxia or other side effects noted.

<span class="mw-page-title-main">PHA-57378</span> Chemical compound

PHA-57378 is a drug which acts as an agonist at serotonin 5-HT2 receptors, having a binding affinity of 4.1 nM at the 5-HT2A subtype and 4.3 nM at 5-HT2C. It has anxiolytic effects in animal studies.

<span class="mw-page-title-main">Droxinavir</span> Chemical compound

Droxinavir was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.

Farmitalia was an Italian pharmaceutical company best known for its parallel discovery with Rhone-Poulenc of daunorubicin and subsequent discovery of doxorubicin. Farmitalia had been founded in 1935 as a joint venture by Rhone-Poulenc and Montecatini. Farmitalia occupied a position of choice in the world rankings of the profession, not only in Italy, but also at the world level with in particular the patent of Adriamycin, an anti-cancer drug qualified. From its creation, Farmaceutici Italia buys the Schiapparelli factory.

References

  1. Breimer DD, de Boer AG (1976). "Pharmacokinetics and relative bioavailability of vinylbital in man after oral and rectal administration". Arzneimittel-Forschung. 26 (3): 448–54. PMID   989344.
  2. US 2868790,Brandstrom AE,"Manufacture of Barbituric Acid Compounds",issued 13 January 1959, assigned to Pharmacia